Form 4: Privia Health Director Trades Under 10b5-1 Plan

Privia Health Group, Inc. Director Matthew Shawn Morris executed trades under a pre-arranged 10b5-1 plan, selling a significant number of shares and exercising stock options.

Summary

• Matthew Shawn Morris, a Director at Privia Health Group, Inc., engaged in stock transactions on July 2, 2026, and July 6, 2026, under a Rule 10b5-1 trading plan.
• On July 2, 2026, Morris acquired 59,037 shares of common stock at $2 per share and disposed of 59,037 shares at a weighted average price of $27.33.
• On July 6, 2026, Morris acquired an additional 53,722 shares of common stock at $2 per share and disposed of 53,722 shares at a weighted average price of $27.24.
• The filing also notes the forfeiture of 8,463 unvested restricted stock units granted on May 20, 2026.
• As of the reporting date, Morris beneficially owns 76,651 shares directly and has indirect ownership of 12,487 shares through Emerald Family, LLC, and 11,998 shares through a Trust.
• Derivative securities, specifically stock options, were also exercised. On July 2, 2026, 59,037 options were exercised at a price of $2, and on July 6, 2026, 53,722 options were exercised at $2.
• All reported stock options are fully vested and exercisable, with an expiration date of August 27, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-established 10b5-1 plan, which is a standard and regulated method for insiders to trade securities.

Positives

• Director Matthew Shawn Morris continues to hold a substantial number of shares indirectly through Emerald Family, LLC (12,487 shares) and a Trust (11,998 shares).
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive sales.
• All stock options exercised are fully vested, demonstrating the realization of equity compensation.

Negatives

• Director Matthew Shawn Morris disposed of a significant number of shares, totaling 112,759 shares across two transaction dates.
• The forfeiture of 8,463 unvested restricted stock units indicates a loss of potential future equity for the reporting person.

Risks

• The disposal of a large number of shares by a director could be interpreted negatively by the market, potentially impacting share price.
• While executed under a 10b5-1 plan, the sheer volume of shares sold might raise concerns about the director's confidence in future stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives and directors to diversify holdings or manage personal finances. The execution of these trades by a director of Privia Health Group, Inc. is a standard disclosure requirement.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the director's stock sales, potentially influencing short-term trading sentiment, though the 10b5-1 plan mitigates concerns about insider knowledge.
• Employees: The forfeiture of unvested RSUs could be noted, but the primary impact is on the reporting individual.
• Management: The transactions are a routine part of executive compensation realization and portfolio management.

Key Dates

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, 10b5-1 Plan, Stock Options, Restricted Stock Units, Director Transactions, Beneficial Ownership, Securities Exchange Act